Jan Alsner

Analytical validity of CD20 as a biomarker in breast cancer patients using tissue microarrays and whole slide sections

Background Clinical utility of biomarker-based treatment depends on both analytical and clinical validity. CD20+ B-lymphocytes often form nodular lymphoid structures within tumors, presenting potential analytical issues if using tissue microarrays (TMA). We compared CD20 expressi...